Chronic Obstructive Pulmonary Disease (COPD): Market Assessment, Epidemiology & Market Forecast-2028
This report can be delivered to the clients within 7-10 Business Days.
CmaxInsight’s “Acute Ischemic Stroke: Market Assessment, Epidemiology & Market Forecast-2028” report provides an overview of the disease and market size of Acute Ischemic Stroke for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers epidemiology of Acute Ischemic Stroke from 2018 to 2028 segmented by seven major markets market along with market drivers, market barriers and unmet medical needs of this indication.
Research Scope
Acute Ischemic Stroke Overview and Treatment Landscape
The report provides comprehensive information of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Acute Ischemic Stroke in the United States, Europe, and Japan are also covered.
Acute Ischemic Stroke Epidemiology
This section of the report provides the country-specific information of historical and current patient pool and offers forecasted value for prevalent/ incident cases, along with diagnosed and treatable patient pool.
Acute Ischemic Stroke Marketed and Emerging Drug Landscape
A snapshot on the marketed and pipeline emerging drugs, along with comprehensive insight on emerging treatments based on their safety & efficacy results, mechanism of action, route of administration, therapeutic potential, regulatory success, launch dates, and other factors.
This section also covers latest news which includes agreements and collaborations, approvals, patent details and other major breakthroughs.
Acute Ischemic Stroke Market Size and Segmentation
This segment of the report focuses on key question: “What is the size of the total & addressable market for Acute Ischemic Stroke”? This key question will help to answer whether the market is big enough to be interested in your business. Relevant and detailed patient segmentations are provided for each Indication, enabling to evaluate the commercial potential of the market.
Acute Ischemic Stroke Market Trends and Opportunities
Identify market trends and the opportunities by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
Acute Ischemic Stroke Unmet Needs
Discover the significant current and future unmet needs for the Acute Ischemic Stroke. Market requirements vary with different countries and geographies.
Methodologies
Our experts synthesize information from proprietary databases, syndicated reports, primary research and secondary data, such as company reports, press releases, published peer-reviewed journal articles, disease registries, and general news media to provide a complete picture of your market. Our approach ensures that every data point and inference goes through multiple validations while leveraging a variety of sources to formulate market and opportunity size.
Key Coverage and Benefits:
CmaxInsight’s “Acute Ischemic Stroke: Market Assessment, Epidemiology & Market Forecast-2028” report provides an overview of the disease and market size of Acute Ischemic Stroke for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers epidemiology of Acute Ischemic Stroke from 2018 to 2028 segmented by seven major markets market along with market drivers, market barriers and unmet medical needs of this indication.
Research Scope
Acute Ischemic Stroke Overview and Treatment Landscape
The report provides comprehensive information of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Acute Ischemic Stroke in the United States, Europe, and Japan are also covered.
Acute Ischemic Stroke Epidemiology
This section of the report provides the country-specific information of historical and current patient pool and offers forecasted value for prevalent/ incident cases, along with diagnosed and treatable patient pool.
Acute Ischemic Stroke Marketed and Emerging Drug Landscape
A snapshot on the marketed and pipeline emerging drugs, along with comprehensive insight on emerging treatments based on their safety & efficacy results, mechanism of action, route of administration, therapeutic potential, regulatory success, launch dates, and other factors.
This section also covers latest news which includes agreements and collaborations, approvals, patent details and other major breakthroughs.
Acute Ischemic Stroke Market Size and Segmentation
This segment of the report focuses on key question: “What is the size of the total & addressable market for Acute Ischemic Stroke”? This key question will help to answer whether the market is big enough to be interested in your business. Relevant and detailed patient segmentations are provided for each Indication, enabling to evaluate the commercial potential of the market.
Acute Ischemic Stroke Market Trends and Opportunities
Identify market trends and the opportunities by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
Acute Ischemic Stroke Unmet Needs
Discover the significant current and future unmet needs for the Acute Ischemic Stroke. Market requirements vary with different countries and geographies.
Methodologies
Our experts synthesize information from proprietary databases, syndicated reports, primary research and secondary data, such as company reports, press releases, published peer-reviewed journal articles, disease registries, and general news media to provide a complete picture of your market. Our approach ensures that every data point and inference goes through multiple validations while leveraging a variety of sources to formulate market and opportunity size.
Key Coverage and Benefits:
- The report will help in developing business strategies by understanding the trends shaping and driving the global Acute Ischemic Stroke market.
- The report provides detailed historical and forecasted epidemiological data of Acute Ischemic Stroke in the 7MM from 2018-2028.
- Organize sales and marketing efforts by identifying the best opportunities for Acute Ischemic Stroke in US, Europe and Japan.
- To understand the future market competition in the global Acute Ischemic Stroke and insightful review of the key market drivers and barriers.
- To understand the regulatory scenario in major markets.
1. REPORT INTRODUCTION
2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET OVERVIEW AT GLANCE
3. DISEASE BACKGROUND AND OVERVIEW: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
3.1. Introduction
3.2. Signs and Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnostic Landscape
3.6.1. Diagnostic Practices
3.6.2. Diagnostic Criteria
3.6.3. Diagnostic Recommendations
3.7. Treatment Landscape
3.7.1. Current Treatment Practices
3.7.2. Treatment Algorithm
3.7.3. Treatment Recommendations
4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) EPIDEMIOLOGY
4.1. Key Findings
4.2. Assumptions & Rationale
4.3. 7MM Epidemiology
5. EPIDEMIOLOGY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BY COUNTRIES
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.1.3. Sub-Type Specific cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.1.4. Sex- Specific Cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.1.5. Diagnosed Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.1.6. Treatable Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.2. Germany
5.2.1. Assumptions and Rationale
5.2.2. Prevalent/Incident Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.2.3. Sub-Type Specific cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.2.4. Sex- Specific Cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.2.5. Diagnosed Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.2.6. Treatable Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.3. France
5.3.1. Assumptions and Rationale
5.3.2. Prevalent/Incident Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.3.3. Sub-Type Specific cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.3.4. Sex- Specific Cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.3.5. Diagnosed Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.3.6. Treatable Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.4. United Kingdom
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.4.3. Sub-Type Specific cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.4.4. Sex- Specific Cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.4.5. Diagnosed Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.4.6. Treatable Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.5. Spain
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.5.3. Sub-Type Specific cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.5.4. Sex- Specific Cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.5.5. Diagnosed Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.5.6. Treatable Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.6.3. Sub-Type Specific cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.6.4. Sex- Specific Cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.6.5. Diagnosed Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.6.6. Treatable Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.7. Japan
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.7.3. Sub-Type Specific cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.7.4. Sex- Specific Cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.7.5. Diagnosed Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.7.6. Treatable Cases of Chronic Obstructive Pulmonary Disease (COPD)
6. UNMET NEEDS
7. MARKETED DRUGS
7.1. Drug
7.1.1. Product Description
7.1.2. Mechanism of Action
7.1.3. Regulatory Milestones
7.1.4. Safety and Efficacy
7.1.5 Side-Effects
7.1.6. Product Profile
7.1.7. Sales
7.1.8. Patent Data
8. EMERGING DRUGS
8.1. Drug
8.1.1. Product Description
8.1.2. Clinical Trial Information and Results
8.1.3. Product Development Activity
8.1.4. Regulatory Milestones
8.1.5. Product Profile
8.1.6. Expected Launch Date
9. COUNTRY SPECIFIC MARKET ANALYSIS
9.1. 7 Major Market Analysis
9.1.1. 7 Major Market Size
9.1.2. Therapy Wise Market Size
9.2. United States Market Analysis
9.2.1. United States Market Size
9.2.2. Therapy Wise Market Size
9.3. Germany Market Analysis
9.3.1. Germany Market Size
9.3.2. Therapy Wise Market Size
9.4. France Market Analysis
9.4.1. France Market Size
9.4.2. Therapy Wise Market Size
9.5. United Kingdom Market Analysis
9.5.1. United Kingdom Market Size
9.5.2. Therapy Wise Market Size
9.6. Spain Market Analysis
9.6.1. Spain Market Size
9.6.2. Therapy Wise Market Size
9.7. Italy Market Analysis
9.7.1. Italy Market Size
9.7.2. Therapy Wise Market Size
9.8. Japan Market Analysis
9.8.1. Japan Market Size
9.8.2. Therapy Wise Market Size
10. MARKET DRIVERS
11. MARKET BARRIERS
12. MARKET OPPORTUNITIES
Appendix
Report Methodology
Sources Used
Disclaimer
About CmaxInsight
*Indication Specific
Note: Certain sections of the table of contents would vary according to the availability of information.
2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET OVERVIEW AT GLANCE
3. DISEASE BACKGROUND AND OVERVIEW: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
3.1. Introduction
3.2. Signs and Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnostic Landscape
3.6.1. Diagnostic Practices
3.6.2. Diagnostic Criteria
3.6.3. Diagnostic Recommendations
3.7. Treatment Landscape
3.7.1. Current Treatment Practices
3.7.2. Treatment Algorithm
3.7.3. Treatment Recommendations
4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) EPIDEMIOLOGY
4.1. Key Findings
4.2. Assumptions & Rationale
4.3. 7MM Epidemiology
5. EPIDEMIOLOGY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BY COUNTRIES
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.1.3. Sub-Type Specific cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.1.4. Sex- Specific Cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.1.5. Diagnosed Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.1.6. Treatable Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.2. Germany
5.2.1. Assumptions and Rationale
5.2.2. Prevalent/Incident Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.2.3. Sub-Type Specific cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.2.4. Sex- Specific Cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.2.5. Diagnosed Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.2.6. Treatable Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.3. France
5.3.1. Assumptions and Rationale
5.3.2. Prevalent/Incident Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.3.3. Sub-Type Specific cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.3.4. Sex- Specific Cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.3.5. Diagnosed Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.3.6. Treatable Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.4. United Kingdom
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.4.3. Sub-Type Specific cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.4.4. Sex- Specific Cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.4.5. Diagnosed Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.4.6. Treatable Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.5. Spain
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.5.3. Sub-Type Specific cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.5.4. Sex- Specific Cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.5.5. Diagnosed Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.5.6. Treatable Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.6.3. Sub-Type Specific cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.6.4. Sex- Specific Cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.6.5. Diagnosed Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.6.6. Treatable Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.7. Japan
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.7.3. Sub-Type Specific cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.7.4. Sex- Specific Cases of Chronic Obstructive Pulmonary Disease (COPD)*
5.7.5. Diagnosed Cases of Chronic Obstructive Pulmonary Disease (COPD)
5.7.6. Treatable Cases of Chronic Obstructive Pulmonary Disease (COPD)
6. UNMET NEEDS
7. MARKETED DRUGS
7.1. Drug
7.1.1. Product Description
7.1.2. Mechanism of Action
7.1.3. Regulatory Milestones
7.1.4. Safety and Efficacy
7.1.5 Side-Effects
7.1.6. Product Profile
7.1.7. Sales
7.1.8. Patent Data
8. EMERGING DRUGS
8.1. Drug
8.1.1. Product Description
8.1.2. Clinical Trial Information and Results
8.1.3. Product Development Activity
8.1.4. Regulatory Milestones
8.1.5. Product Profile
8.1.6. Expected Launch Date
9. COUNTRY SPECIFIC MARKET ANALYSIS
9.1. 7 Major Market Analysis
9.1.1. 7 Major Market Size
9.1.2. Therapy Wise Market Size
9.2. United States Market Analysis
9.2.1. United States Market Size
9.2.2. Therapy Wise Market Size
9.3. Germany Market Analysis
9.3.1. Germany Market Size
9.3.2. Therapy Wise Market Size
9.4. France Market Analysis
9.4.1. France Market Size
9.4.2. Therapy Wise Market Size
9.5. United Kingdom Market Analysis
9.5.1. United Kingdom Market Size
9.5.2. Therapy Wise Market Size
9.6. Spain Market Analysis
9.6.1. Spain Market Size
9.6.2. Therapy Wise Market Size
9.7. Italy Market Analysis
9.7.1. Italy Market Size
9.7.2. Therapy Wise Market Size
9.8. Japan Market Analysis
9.8.1. Japan Market Size
9.8.2. Therapy Wise Market Size
10. MARKET DRIVERS
11. MARKET BARRIERS
12. MARKET OPPORTUNITIES
Appendix
Report Methodology
Sources Used
Disclaimer
About CmaxInsight
*Indication Specific
Note: Certain sections of the table of contents would vary according to the availability of information.
LIST OF TABLES
Table 1: Total Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in 7MM
Table 2: Total Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States
Table 4: Sub-Type Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States*
Table 5: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States*
Table 6: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States
Table 7: Treated Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States
Table 8: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany
Table 9: Sub-Type Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany*
Table 10: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany*
Table 11: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany
Table 12: Treated Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany
Table 13: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France
Table 14: Sub-Type Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France*
Table 15: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France*
Table 16: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France
Table 17: Treated Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France
Table 18: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy
Table 19: Sub-Type Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy*
Table 20: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy*
Table 21: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy
Table 22: Treated Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy
Table 23: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain
Table 24: Sub-Type Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain*
Table 25: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain*
Table 26: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain
Table 27: Treated Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain
Table 28: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK
Table 29: Sub-Type Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK*
Table 30: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK*
Table 31: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK
Table 32: Treated Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK
Table 33: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan
Table 34: Sub-Type Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan*
Table 35: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan*
Table 36: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan
Table 37: Treated Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan
Table 38: Marketed Drugs
Table 39: Pipeline Drugs
Table 40:7MM- Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 41:7MM- Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 42:7MM- Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 43: United States-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 44: United States-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 45: United States-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 46: Germany-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 47: Germany-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 48: Germany-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 49: France-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 50: France-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 51: France-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 52: Italy-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 53: Italy-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 54: Italy-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 55: Spain-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 56: Spain-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 57: Spain-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 58: UK-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 59: UK-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 60: UK-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 61: Japan-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 62: Japan-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 63: Japan-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
*Indication Specific
Table 1: Total Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in 7MM
Table 2: Total Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States
Table 4: Sub-Type Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States*
Table 5: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States*
Table 6: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States
Table 7: Treated Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States
Table 8: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany
Table 9: Sub-Type Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany*
Table 10: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany*
Table 11: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany
Table 12: Treated Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany
Table 13: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France
Table 14: Sub-Type Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France*
Table 15: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France*
Table 16: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France
Table 17: Treated Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France
Table 18: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy
Table 19: Sub-Type Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy*
Table 20: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy*
Table 21: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy
Table 22: Treated Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy
Table 23: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain
Table 24: Sub-Type Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain*
Table 25: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain*
Table 26: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain
Table 27: Treated Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain
Table 28: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK
Table 29: Sub-Type Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK*
Table 30: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK*
Table 31: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK
Table 32: Treated Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK
Table 33: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan
Table 34: Sub-Type Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan*
Table 35: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan*
Table 36: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan
Table 37: Treated Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan
Table 38: Marketed Drugs
Table 39: Pipeline Drugs
Table 40:7MM- Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 41:7MM- Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 42:7MM- Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 43: United States-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 44: United States-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 45: United States-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 46: Germany-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 47: Germany-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 48: Germany-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 49: France-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 50: France-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 51: France-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 52: Italy-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 53: Italy-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 54: Italy-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 55: Spain-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 56: Spain-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 57: Spain-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 58: UK-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 59: UK-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 60: UK-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 61: Japan-Market Size of Chronic Obstructive Pulmonary Disease (COPD) in USD MM
Table 62: Japan-Market Share Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
Table 63: Japan-Market Sales of Chronic Obstructive Pulmonary Disease (COPD) by Therapies in USD MM
*Indication Specific
GlobalData estimates the 2018 COPD drug sales to be $10.9B across the 7MM covered in this report. By the end of the forecast period in 2028, sales will increase to $19.3B, which includes seven pipeline therapies.
The COPD market is mature with an abundance of drug options available, all of which work relatively well; however, there is still room for improvement. COPD is a market with a substantial number of unattained unmet needs, including stakeholders’ recognition of symptoms, treatment that reverses the progression of COPD, and identification of biomarkers and appropriate prescribing of medication.
This is not common for a disease with such an established platform of treatment management and numerous marketed drugs. This is because of the multifactorial causes of the disease combined with a low diagnosis rate across the 7MM. COPD is named the “smoker’s disease” since many of the afflicted individuals are or have been smokers for a lengthy period of their lives.
Occupational exposure including to organic and inorganic dusts, chemical agents, and fumes are under-appreciated as a risk factor for COPD with approximately 20% of cases attributed to workplace exposures. While smokers are warned that smoking is harmful for their health, most are unaware of the prevalence and risks of COPD and many fear the stigma of being labelled with a diagnosis. As a result, many patients avoid seeking help until it is too late and the disease has advanced significantly.
